$OXBDF

Oxford Biomedica reported its Q4 earnings, showing significant growth in revenue attributed to its expanding gene therapy platform. The company also announced new partnerships which are expected to enhance its market position. However, challenges in scaling production were mentioned that could impact future earnings. Overall, the outlook remains positive due to the strong demand for gene therapies. Analysts are optimistic about the company's long-term potential despite some short-term hurdles.